This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Annabel Grewenig - Innovator in Cancer Research
Introduction
Annabel Grewenig is a dedicated inventor based in Heidelberg, Germany. She is affiliated with the Deutsches Krebsforschungszentrum - Stiftung Des Öffentlichen Rechts / Universität Heidelberg. Her work focuses on advancing cancer treatment through innovative research and applications.
Latest Patent Applications
Annabel Grewenig has filed a patent application titled "Method for Predicting the Clinical Response of Oncolytic Parvovirus H1 (H-1PV) Treatment in a Patient Suspected of Suffering from Cancer by Measuring the Expression Levels of Laminins and/or Galectins as Biomarkers in a Patient's Sample." This invention concerns the use of laminins and/or galectins as biomarkers for predicting the outcome of treatment with oncolytic parvovirus H1 in cancer patients.
Conclusion
Annabel Grewenig's contributions to cancer research highlight her commitment to improving patient outcomes through innovative methodologies. Her work in developing predictive biomarkers is a significant step forward in the field of oncology.